Literature DB >> 7919450

In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil.

M P Findlay1, M O Leach.   

Abstract

Since 5-fluorouracil (5-FU) was synthesized in the late 1950s it has become an important component of many anticancer treatment regimens. The increasing volume of literature accumulating about this drug is evidence that the optimal administration schedule and its combination with modulators has yet to be determined. Much of the investigation of 5-FU, particularly in the clinical setting, has been in the development of administration schedules based on plasma pharmacokinetic data. Particularly with the development of modulators of 5-FU, investigators are looking more closely at its intracellular tissue pharmacology and metabolism. To study the tissue metabolism of 5-FU (and other drugs), patients often have to be willing to undergo invasive procedures, sometimes with significant discomfort, usually with little direct benefit to their management. The ability to conduct an investigation of the cellular effects of a drug in both tumor and normal tissue non-invasively will not only be more acceptable to patients, resulting in better compliance to protocols, but will give information about the in situ tissue which is not subject to the problems of invasive sampling techniques. Magnetic resonance spectroscopy is a non-invasive technique that has recently started to show potential in the area of investigating 5-FU metabolism and its impact on tumor and patient outcome. Further development of this method may ultimately have an impact on the investigation of any new anticancer agent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919450     DOI: 10.1097/00001813-199406000-00002

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  5 in total

1.  Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivoF magnetic resonance spectroscopy.

Authors:  Geoffrey S Payne; David J Collins; Peter Loynds; Graham Mould; Philip S Murphy; Andrzej S K Dzik-Jurasz; Preminda Kessar; Nazneen Haque; Masayuki Yamaguchi; Shogo Atarashi; Martin O Leach
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

2.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research.

Authors:  John Kurhanewicz; Daniel B Vigneron; Kevin Brindle; Eduard Y Chekmenev; Arnaud Comment; Charles H Cunningham; Ralph J Deberardinis; Gary G Green; Martin O Leach; Sunder S Rajan; Rahim R Rizi; Brian D Ross; Warren S Warren; Craig R Malloy
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

3.  Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model.

Authors:  D Burke; P Carnochan; C Glover; T G Allen-Mersh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?

Authors:  Dominick J O McIntyre; Franklyn A Howe; Christophe Ladroue; Fiona Lofts; Marion Stubbs; John R Griffiths
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-07       Impact factor: 3.333

5.  Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells.

Authors:  A S Ojugo; P M McSheehy; M Stubbs; G Alder; C L Bashford; R J Maxwell; M O Leach; I R Judson; J R Griffiths
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.